GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Apple

Amazon

Salesforce

Medtronic

Microsoft

Palantir Technologies

In the dynamic world of investing, there's always a buzz surrounding “smart money” stocks. This excitement isn't just about fleeting market trends; it's rooted in the savvy market decisions made by individuals with incredible financial acumen.

7 ‘Smart Money' Stocks Set to Explode Higher

GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due to patent expirations. GSK has a strong balance sheet, high margins, and a sound revenue track record, making it a compelling value investment.

GSK: Strong Positioning And Trading At Historical Discount

GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection.

GSK lifts growth ambitions for HIV business on long-acting drug

The company is not dependent on the success or failure of one individual drug.

Best Dividend Stocks: British Giant GSK Offers Yield, Security For Investors

Pfizer

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for use of the first vaccine for respiratory syncytial virus (RSV) approved for pregnant women to protect their babies.

Explainer: What you need to know about RSV and the new vaccines

Merck

Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the second quarter of 2023, up 8.1% year-over-year, beating analysts' estimates by $0.38 billion. Meanwhile, Merck's revenue continued to grow quarter over quarter and reached approximately $15.04 billion for the three months ended June 30, 2023.

Merck Vs. GSK: The Game-Changer Race In Pharma Excellence

The European Commission (EC) has authorised GSK PLC (LSE:GSK, NYSE:GSK) subsidiary ViiV Healthcare's HIV-prevention drug Apretude. Known scientifically as cabotegravir, Apretude can be used in combination with safe-sex practices to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents.

GSK's HIV-prevention drug Apretude approved by European Commission

The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.

European Commission authorises GSK's HIV prevention drug

GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.

GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia

Incyte

Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that will compete with Incyte's Jakafi. The FDA approved Ojjaara for use in patients with myelofibrosis, a rare blood cancer, with anemia.

Incyte shares drop after FDA approves GSK's competing blood-cancer treatment

British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type of bone marrow cancer called myelofibrosis.

US FDA approves GSK's anemia treatment

The European Medicines Agency's human medicines committee on Friday recommended against renewal of the conditional marketing authorisation for GSK's blood cancer drug Blenrep.

EU regulator recommends to stop sale of GSK's blood cancer drug

GSK has opened a new £65 million drug factory in Hertfordshire in a move it said would enable rapid production of medicines developed through its research pipeline. In contrast to UK rival AstraZeneca, which chose to build a new US$400m factory in Ireland earlier this year, GSK has plumped for Ware, the site of its life science campus that already employs around 1,350 people AstraZeneca blamed the UK's “very unattractive” tax decisions for its decision, adding it had originally planned to build its plant in England's northwest.

GSK opens new site in UK unlike rival AstraZeneca

GSK plc (NYSE:GSK ) BofA Global Healthcare Conference September 14, 2023 4:05 AM ET Company Participants Emma Walmsley - Chief Executive Officer Julie Brown - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Graham Parry Good morning, everybody and welcome to Session 2 of the Second Day of the Bank of America Global Healthcare Conference today. It's my pleasure to be able to introduce our first European company of the morning, which is GSK.

GSK plc (GSK) Presents at BofA Global Healthcare Conference (Transcript)

GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

GSK (GSK) Moves 5.5% Higher: Will This Strength Last?

Organon & Co

Viatris

Viatris, known for its branded drugs, has several up-and-coming biosimilars. GSK is seeing sales growth even as its COVID-19-related sales decline.

3 Pharmaceutical Stocks That Are Too Cheap to Ignore

Adyen NV

Bayer AG

British American Tobacco

Anheuser-Busch InBev

Imperial Brands PLC

JD.com

Omron Corp

Roche Holding AG

Sanofi

Tencent Holdings Limited

Taiwan Semiconductor Manufacturing

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for.

International Wide-Moat Stocks On Sale - The September 2023 Heat Map

GSK plc (NYSE:GSK ) Citi's 18th Annual BioPharma Conference September 7, 2023 8:50 AM ET Company Participants Phil Dormitzer - SVP, Head of Vaccines R&D Conference Call Participants Andrew Baum - Citi Andrew Baum So delighted to introduce our next speakers from GSK, Phil Dormitzer. Phil is Senior Vice President, Head of Vaccines Research and Development.

GSK plc (GSK) Citi's 18th Annual BioPharma Conference Transcript

Several UK oil refineries owned by Ineos, along with power stations, chemical and sites, including for Esso, Essar and GSK PLC (LSE:GSK, NYSE:GSK) are facing disruption from potential strikes over a dispute with contractors over pay, which has not been increased since early 2022.  More than 3,000 engineering construction workers are being balloted over pay by trade union Unite under the National Agreement for Engineering Construction Industry (NAECI).

Ineos, Esso and GSK face potential strikes as contractors balloted over pay dispute

PHILADELPHIA--(BUSINESS WIRE)--GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations.

GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

JPMorgan Chase & Co

NVIDIA

Thermo Fisher Scientific

Walmart

Emulating the moves of hedge fund stock pickers, and some of the most successful hedge funds can produce sizable profits for retail investors. In fact, here are seven of the top institutional stock picks you may want to consider as we near the last few months of 2023.

7 Stocks Hedge Funds Are Loading Up On

GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japanese authorities have accepted for review a supplementary new drug application (sNDA) for Nucala,  a treatment for chronic rhinosinusitis with nasal polyps in adult patients. If approved, Nucala would be the first anti-interleukin-5 biologic available in Japan for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal polyps, the firm said.

GSK's new drug application for Nucala accepted for review in Japan

Match Group

Ubisoft Entertainment SA

Stocks are rallying once again in 2023. The growth-oriented index is leading the way higher with a 36% gain or more than twice the return of the S&P 500.

3 Growth Stocks to Ride the Coming Bull Market in Style

GSK PLC (LSE:GSK, NYSE:GSK) announced that its Shingrix vaccine demonstrated 100% efficacy in preventing shingles among adults aged 50 and over in China. The data comes from the first efficacy trial of Shingrix in the country, involving nearly 6,000 participants.

GSK's Shingrix proves 100% effective against shingles in China trial

Apellis Pharma

Bristol-Myers

Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery.

3 Sorry Pharma Stocks to Sell in August Before It's Too Late

News for GlaxoSmithKline Stock (GSK)